(1) World Medical Association. WMA Declaration of Helsinki – Ethical principles for medical research involving human subjects. 2008. [Cited 2012 Sept 25]. Available from: http://www.wma.net/en/30publications/10policies/b3/index.html
(2) Pildal J, Chan A-W, Hróbjartsson A, Forfang E, Altman DG, Gøtzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BMJ 2005;330:1049.
(3) Hróbjartsson A, Pildal J, Chan A-W, Haahr MT, Altman DG, Gøtzsche PC. Reporting on blinding in trial protocols and corresponding publications was often inadequate but rarely contradictory. J Clin Epidemiol 2009;62:967-973.
(4) Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-2465.
(6) Chan A-W, Hróbjartsson A, Jørgensen KJ, Gøtzsche PC, Altman DG. Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ 2008;337:a2299.
(8) Hernández AV, Steyerberg EW, Taylor GS, Marmarou A, Habbema JD, Maas AI. Subgroup analysis and covariate adjustment in randomized clinical trials of traumatic brain injury: a systematic review. Neurosurgery 2005;57:1244-1253.
(11) Mhaskar R, Djulbegovic B, Magazin A, Soares HP, Kumar A. Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. J Clin Epidemiol 2012;65:602-609.
(14) Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K et al. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med 2013. In press (Online First version).
(17) Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
(18) Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1-34.
(19) Warner Chilcott. A comparison of once a day dose compared to 2 doses/day. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2012 Sept 25]. Available from: http://clinicaltrials.gov/show/NCT00505778 NLM Identifier: NCT00505778.
(20) Dickersin K, Manheimer E, Wieland S, Robinson KA, Lefebvre C, McDonald S. Development of the Cochrane Collaboration’s CENTRAL Register of controlled clinical trials. Eval Health Prof 2002;25:38-64.
(21) Shaw L, Price C, McLure S, Howel D, McColl E, Ford GA. Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST): study protocol for a pilot randomised controlled trial [protocol]. Trials 2011;12:152.
(24) Krleža-Jerić K, Chan A-W, Dickersin K, Sim I, Grimshaw J, Gluud C for the Ottawa Group. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). BMJ 2005;330:956-958.
(25) DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA 2004;292:1363-1364.
(28) You B, Gan HK, Pond G, Chen EX. Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review. J Clin Oncol 2012;30:210-216.
(29) United States Congress. Food and Drug Administration Amendments Act of 2007, Title VIII, Section 801. Expanded clinical trial registry data bank. 2007. [Cited 2012 Sept 25]. Available from: http://www.govtrack.us/congress/billtext.xpd?bill=h110-3580
(30) European Commission. Communication from the Commission regarding the guideline on the data fields contained in the clinical trials database provided for in Article 11 of Directive 2001/20/EC to be included in the database on medicinal products provided for in Article 57 of Regulation (EC) No 726/2004 (2008/C 168/02). Official Journal of the European Union 2008;51:3-4.
(32) Bernhard Nocht Institute for Tropical Medicine. Probiotic saccharomyces boulardii for the prevention of antibiotic-associated diarrhoea (SacBo). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2012 Sept 25]. Available from: http://clinicaltrials.gov/ct2/show/NCT01143272 NLM Identifier: NCT01143272.
(33) Protocol SB-275833/030 – Studies 030A and 030B: Two identical double-blind, double-dummy, multicenter, comparative phase III studies of the safety and efficacy of topical 1% SB-275833, applied twice daily, versus oral Cephalexin, 500 mg in adults, or 12.5 mg/kg (250 mg/5 ml) in children, twice daily, in the treatment of uncomplicated secondarily infected traumatic lesions [protocol]. Version 5 (July 25, 2005). Available from: http://www.spirit-statement.org/wp-content/uploads/2012/12/Protocol-SB-275833.pdf
(34) Effect of tranexamic acid on coagulation in a sample of participants in the WOMAN trial: WOMAN-ETAC study [protocol]. Version 1 (August 3, 2011). [Cited 2012 Sept 25]. Available from:
(39) Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006;163:185-194.
(40) Djulbegovic B, Cantor A, Clarke M. The importance of preservation of the ethical principle of equipoise in the design of clinical trials: relative impact of the methodological quality domains on the treatment effect in randomized controlled trials. Account Res 2003;10:301-315.
(41) Etter J-F, Burri M, Stapleton J. The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis. Addiction 2007;102:815-822.
(43) Min Y-I, Unalp-Arida A, Scherer R, Dickersin K. Assessment of equipoise using a cohort of randomized controlled trials [abstract]. International Congress on Peer Review and Biomedical Publication; 2005 Sept 16-18; Chicago, Illinois, USA 2005.
(46) The Danish National Committee on Biomedical Research Ethics. Guidelines about Notification etc. of a Biomedical Research Project to the Committee System on Biomedical Research Ethics No 9154, 5 May 2011. 2011. [Cited 2012 Sept 25]. Available from: http://www.cvk.sum.dk/English/guidelinesaboutnotification.aspx
(49) Trials. Instructions for authors – study protocols. 2012. [Cited 2012 Sept 25]. Available from: http://www.trialsjournal.com/authors/instructions/studyprotocol#formatting-contributions
(50) Williams H. The Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Study. A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid [protocol]. Version 4.0 (July 20, 2011). [Cited 2012 Sept 25]. Available from: http://www.spirit-statement.org/wp-content/uploads/2012/12/Blister-Protocol-v4-20July2011.pdf
(51) Gertel A, Block P, Gawrylewski H-M, Raymond S, Quinn T, Muhlbradt E. CDISC Clinical Research Glossary. Version 8.0. 2009. [Cited 2012 Sept 25]. Available from: http://www.cdisc.org/stuff/contentmgr/files/0/be650811feb46f381f0af41ca40ade2e/misc/cdisc_2009_glossary.pdf
(52) World Health Organization. Operational guidelines for ethics committees that review biomedical research. 2000. [Cited 2012 Sept 25]. Available from: http://www.who.int/tdr/publications/documents/ethics.pdf
(53) World Health Organization. Handbook for good clinical research practice (GCP): Guidance for implementation. 2002. [Cited 2012 Sept 25]. Available from: http://apps.who.int/prequal/info_general/documents/GCP/gcp1.pdf
(54) Pierce MA, Hess EP, Kline JA, Shah ND, Breslin M, Branda ME, et al. The Chest Pain Choice trial: a pilot randomized trial of a decision aid for patients with chest pain in the emergency department [protocol]. Trials 2010;11:57.
(58) Montgomery JH, Byerly M, Carmody T, Li B, Miller DR, Varghese F et al. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials 2004;25:598-612.
(59) Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 2005;162:1957-1960.
(60) Jagsi R, Sheets N, Jankovic A, Motomura AR, Amarnath S, Ubel PA et al. Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research. Cancer 2009;115:2783-2791.
(62) European Vasculitis Study Group (EUVAS). RITUXVAS Clinical Trial Protocol: An international, randomised, open label trial comparing a rituximab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of active, ‘generalised’ ANCA associated vasculitis [protocol]. Version 1b (November 15, 2005). [Cited 2012 Sept 25]. Available from: http://www.vasculitis.nl/media/documents/rituxvas.pdf
(63) Delgado-Rodriguez M, Ruiz-Canela M, De Irala-Estevez J, Llorca J, Martinez-Gonzalez MA. Participation of epidemiologists and/or biostatisticians and methodological quality of published controlled clinical trials. J Epidemiol Community Health 2001;55:569-572.
(64) Llorca J, Martinez-Sanz F, Prieto-Salceda D, Fariñas-Alvarez C, Chinchon MV, Quinones D et al. Quality of controlled clinical trials on glaucoma and intraocular high pressure. J Glaucoma 2005;14:190-195.
(65) CRASH2 Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage: A large randomised placebo controlled trial among trauma patients with or at risk of significant haemorrhage, of the effects of antifibrinolytic treatment on death and transfusion requirement [protocol]. Version 3 (July 2, 2005). [Cited 2012 Sept 25]. Available from: http://www.crash2.lshtm.ac.uk/
(67) Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiauka S et al. Factors that limit the quality, number and progress of randomised controlled trials. Health Technol Assess 1999;3:1-143.
(71) Canadian Institutes of Health Research. RCT evaluation criteria and headings. 2010. [Cited 2012 Sept 25]. Available from: http://www.cihr.ca/e/39187.html
(72) National Institute for Health Research. Efficacy and mechanism evaluation program. Important information & guidance notes – preliminary application. 2012. [Cited 2012 Sept 25]. Available from: http://www.eme.ac.uk/funding/Researcher-led.asp
(74) Puhan MA, Vollenweider D, Steurer J, Bossuyt PM, ter Riet G. Where is the supporting evidence for treating mild to moderate chronic obstructive pulmonary disease exacerbations with antibiotics? A systematic review. BMC Med 2008;6:28.
(78) Goudie AC, Sutton AJ, Jones DR, Donald A. Empirical assessment suggests that existing evidence could be used more fully in designing randomized controlled trials. J Clin Epidemiol 2010;63:983-991.
(83) Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: MR000006. DOI:10.1002/14651858.MR000006.pub3.
(85) A phase III multi-centre, randomised, double-blind, double-dummy, comparative clinical study to assess the safety and efficacy of a fixed-dose formulation of oral pyronaridine artesunate (180:60 mg tablet) versus chloroquine (155 mg tablet), in children and adult patients with acute Plasmodium vivax malaria [protocol]. Version 2.0 (March 5, 2007). [Cited 2012 Sept 25]. Available from: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0014501#s5
(92) Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol 2006;7:141-148.
(95) Sneed JR, Rutherford BR, Rindskopf D, Lane DT, Sackeim HA, Roose SP. Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. Am J Geriatr Psychiatry 2008;16:65-73.
(96) Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 2010;71:270-279.
(98) A phase 3, active (Warfarin) controlled, randomized, double-blind, parallel arm study to evaluate efficacy and safety of Apixaban in preventing stroke and systemic embolism in subjects with nonvalvular atrial fibrillation (ARISTOTLE: Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation) [protocol]. Version 4 (August 4, 2010). [Cited 2012 Sept 25]. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa1107039
(100) Heger U, Voss S, Knebel P, Doerr-Harim C, Neudecker J, Schuhmacher C, et al. Prevention of abdominal wound infection (PROUD trial, DRKS00000390): study protocol for a randomized controlled trial [protocol]. Trials 2011;12:245.
(103) Gilbody S, Bower P, Torgerson D, Richards D. Cluster randomized trials produced similar results to individually randomized trials in a meta-analysis of enhanced care for depression. J Clin Epidemiol 2008;61:160-168.
(105) Khan KS, Daya S, Collins JA, Walter SD. Empirical evidence of bias in infertility research: overestimation of treatment effect in crossover trials using pregnancy as the outcome measure. Fertil Steril 1996;65:939-945.
(113) Project Accept Study Group. Project Accept (HPTN 043): A phase III randomized controlled trial of community mobilization, mobile testing, same-day results, and post-test support for HIV in Sub-Saharan Africa and Thailand [protocol]. Version 2.4 (April 15, 2011). [Cited 2012 Sept 25]. Available from: http://www.hptn.org/research_studies/hptn043.asp
(117) Fabricatore AN, Wadden TA, Moore RH, Butryn ML, Gravallese EA, Erondu NE et al. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev 2009;10:333-341.
(118) Lemieux J, Goodwin PJ, Pritchard KI, Gelmon KA, Bordeleau LJ, Duchesne T et al. Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials. J Clin Oncol 2008;26:4458-4465.
(120) Sood A, Knudsen K, Sood R, Wahner-Roedler DL, Barnes SA, Bardia A et al. Publication bias for CAM trials in the highest impact factor medicine journals is partly due to geographical bias. J Clin Epi 2007;60:1123-1126.
(123) Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness (ESCAPE) [protocol]. Version 3.0 (November 29, 1999). [Cited 2012 Sept 25]. Available from: https://biolincc.nhlbi.nih.gov/studies/escape/?q=escape.
(125) Blümle A, Meerpohl JJ, Rücker G, Antes G, Schumacher M, von Elm E. Reporting of eligibility criteria of randomised trials: cohort study comparing trial protocols with subsequent articles. BMJ 2011;342:d1828.
(127) Simpson F, Sweetman EA, Doig GS. Systematic review of techniques and interventions for improving adherence to inclusion and exclusion criteria during enrolment into randomised controlled trials. Trials 2010;11:17.
(128) Rendell JM, Merritt RK, Geddes JR. Incentives and disincentives to participation by clinicians in randomised controlled trials. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: MR000021. DOI: 10.1002/14651858.MR000021.pub3.
(129) Weijer C. “Characterizing the population in clinical trials: barriers, comparability, and implications for review” (1995). Philosophy Publications. Paper 250. [Cited 2012 Sept 25]. Available from: http://ir.lib.uwo.ca/philosophypub/250.
(132) Van Spall HGC, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007;297:1233-1240.
(134) Gandhi M, Ameli N, Bacchetti P, Sharp GB, French AL, Young M et al. Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS 2005;19:1885-1896.
(138) Blanco C, Olfson M, Goodwin RD, Ogburn E, Liebowitz MR, Nunes EV et al. Generalizability of clinical trial results for major depression to community samples: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2008;69:1276-1280.
(139) Herland K, Akselsen JP, Skjøonsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med 2005;99:11-19.
(141) Zarin DA, Young JL, West JC. Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. Soc Psychiatry Psychiatr Epidemiol 2005;40:27-35.
(142) Hordijk-Trion M, Lenzen M, Wijns W, de Jaegere P, Simoons ML, Scholte op Reimer WJ et al. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J 2006;27:671-678.
(143) Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007;66:1473-1478.
(145) Crossman DC, Morton AC, Gunn JP, Greenwood JP, Hall AS, Fox KA, et al. Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study) [protocol]. Trials 2008;9:8.
(147) Duff JM, Leather H, Walden EO, LaPlant KD, George TJ, Jr. Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application. J Natl Cancer Inst 2010;102:702-705.
(151) Medical Research Council Working Party on Prostate Cancer. MRC PR05. A Medical Research Council randomised trial of adjuvant sodium clodronate in patients commencing or responding to hormone therapy for metastatic prostate adenocarcinoma [protocol]. Feb 1995 version. [Cited 2012 Sept 25]. Available from: http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=60
(152) Panel on Handling Missing Data in Clinical Trials, National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials. Washington D.C.: The National Academies Press; 2010.
(153) Buchbinder S, Liu A, Thompson M, Mayer K. Phase II extended safety study of Tenofovir Disoproxil Fumarate (TDF) among HIV-1 negative men [protocol]. Version 1.6 (February 16, 2007). [Cited 2012 Sept 25]. Available from: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0023688
(154) World Health Organization. Adherence to long-term therapies: evidence for action. 2012. [Cited 2012 Sept 25]. Available from: http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf
(160) International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Good clinical practice, consolidated guideline. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (June 1996, E6). 1996. [Cited 2012 Sept 25]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf
(164) Bhandari M, Lochner H, Tornetta P, III. Effect of continuous versus dichotomous outcome variables on study power when sample sizes of orthopaedic randomized trials are small. Arch Orthop Trauma Surg 2002;122:96-98.
(166) Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ 2012;344:e1119.
(167) Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 2012;157:429-438.
(168) Ferreira-González I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007;334:786.
(176) Dwan K, Altman DG, Cresswell L, Blundell M, Gamble CL, Williamson PR. Comparison of protocols and registry entries to published reports for randomised controlled trials. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No.: MR000031. DOI: 10.1002/14651858.MR000031.pub2.
(181) Booth R, Fuller B, Thompson L, McCarty D, Shoptaw S, et al. STUDY #: NIDA-CTN-0017. HIV and HCV risk reduction interventions in drug detoxification and treatment settings [protocol]. Version 4.0 (August 16, 2010). [Cited 2012 Sept 25]. Available from: https://www.dtmi.duke.edu/crflibrary-demo/crf-library-1/crf-library/trials-a-e/ctn-0017
(182) Cockayne NL, Glozier N, Naismith SL, Christensen H, Neal B, Hickie IB. Internet-based treatment for older adults with depression and co-morbid cardiovascular disease: protocol for a randomised, double-blind, placebo controlled trial [protocol]. BMC Psychiatry 2011;11:10.
(183) McMurran M, Crawford MJ, Reilly JG, McCrone P, Moran P, Williams H, et al. Psycho-education with problem solving (PEPS) therapy for adults with personality disorder: A pragmatic multi-site community-based randomised clinical trial [protocol]. Trials 2011;12:198.
(185) Yazici Y, Adler NM, Yazici H. Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called ‘efficacy and safety’ trials: a survey of power considerations. Rheumatol 2008;47:1054-1057.
(195) Pals SL, Murray DM, Alfano CM, Shadish WR, Hannan PJ, Baker WL. Individually randomized group treatment trials: a critical appraisal of frequently used design and analytic approaches. Am J Pub Health 2008;98:1418-1424.
(197) Eldridge SM, Ashby D, Feder GS, Rudnicka AR, Ukoumunne OC. Lessons for cluster randomized trials in the twenty-first century: a systematic review of trials in primary care. Clin Trials 2004;1:80-90.
(199) Freiman JA, Chalmers TC, Smith H, Jr., Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 “negative” trials. N Engl J Med 1978;299:690-694.
(208) Asthma Clinical Research Network. Beta Adrenergic Response by Genotype (BARGE) Study Protocol: A study to compare the effects of regularly scheduled use of inhaled albuterol in patients with mild to moderate asthma who are members of two distinct haplotypes expressed at the β2 -adrenergic receptor [protocol]. Version 5.4 (September 23, 1999). [Cited 2012 Sept 25]. Available from: https://biolincc.nhlbi.nih.gov/studies/barge/?q=barge
(209) Campbell MK, Snowdon C, Francis D, Elbourne D, McDonald AM, Knights R et al. Recruitment to randomised trials: Strategies for trial enrolment and participation study. The STEPS study. Health Technol Assess 2007;11:iii-72.
(210) Wise P, Drury M. Pharmaceutical trials in general practice: the first 100 protocols. An audit by the clinical research ethics committee of the Royal College of General Practitioners. BMJ 1996;313:1245-1248.
(214) McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials 2006;7:9.
(217) Treweek S, Pitkethly M, Cook J, Kjeldstrøm M, Taskila T, Johansen M et al. Strategies to improve recruitment to randomised controlled trials. Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No.: MR000013. DOI: 10.1002/14651858.MR000013.pub5.
(221) Miller NL, Markowitz JC, Kocsis JH, Leon AC, Brisco ST, Garno JL. Cost effectiveness of screening for clinical trials by research assistants versus senior investigators. J Psychiatr Res 1999;33:81-85.
(222) Tworoger SS, Yasui Y, Ulrich CM, Nakamura H, LaCroix K, Johnston R et al. Mailing strategies and recruitment into an intervention trial of the exercise effect on breast cancer biomarkers. Cancer Epidemiol Biomarkers Prev 2002;11:73-77.
(223) Schroy P.C. 3rd, Glick JT, Robinson P, Lydotes MA, Heeren TC, Prout M et al. A cost-effectiveness analysis of subject recruitment strategies in the HIPAA era: results from a colorectal cancer screening adherence trial. Clin Trials 2009;6:597-609.
(224) Harvey LA, Dunlop SA, Churilov L, Hsueh Y-SA, Galea MP. Early intensive hand rehabilitation after spinal cord injury (“Hands On”): a protocol for a randomised controlled trial [protocol]. Trials 2011;12:14.
(228) Odgaard-Jensen J, Vist GE, Timmer A, Kunz R, Akl EA, Schünemann H et al. Randomisation to protect against selection bias in healthcare trials. Cochrane Database of Systematic Reviews 2011, Issue 4. Art. No.: MR000012. DOI: 10.1002/14651858.MR000012.pub3.
(233) Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-412.
(240) Abbott JH, Robertson MC, McKenzie JE, Baxter GD, Theis J-C, Campbell AJ, et al. Exercise therapy, manual therapy, or both, for osteoarthritis of the hip or knee: a factorial randomised controlled trial protocol [protocol]. Trials 2009;10:11.
(242) Chalmers TC, Levin H, Sacks HS, Reitman D, Berrier J, Nagalingam R. Meta-analysis of clinical trials as a scientific discipline. I: Control of bias and comparison with large co-operative trials. Stat Med 1987;6:315-328.
(244) Herbison P, Hay-Smith J, Gillespie WJ. Different methods of allocation to groups in randomized trials are associated with different levels of bias. A meta-epidemiological study. J Clin Epidemiol 2011;64:1070-1075.
(245) Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: MR000012. DOI: 10.1002/14651858.MR000012.pub2.
(246) Klingberg S, Wittorf A, Meisner C, Wölwer W, Wiedemann G, Herrlich, J, et al. Cognitive behavioural therapy versus supportive therapy for persistent positive symptoms in psychotic disorders: The POSITIVE study, a multicenter, prospective, single-blind, randomised controlled clinical trial [protocol]. Trials 2010;11:123.
(250) Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Bürgi E, Scherer M et al. The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study. BMJ 2009;339:b3244.
(252) Ballintine EJ. Randomized controlled clinical trial. National Eye Institute workshop for ophthalmologists. Objective measurements and the double-masked procedure. Am J Ophthalmol 1975;79:763-767.
(256) Boutron I, Estellat C, Guittet L, Dechartres A, Sackett DL, Hróbjartsson A et al. Methods of blinding in reports of randomized controlled trials assessing pharmacological treatments: a systematic review. PLoS Med 2006;3:e425.
(258) Lieverse R, Nielen MM, Veltman DJ, Uitdehaag BM, van Someren EJ, Smit JH et al. Bright light in elderly subjects with nonseasonal major depressive disorder: a double blind randomised clinical trial using early morning bright blue light comparing dim red light treatment. Trials 2008;9:48.
(259) Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA 2001;285:2000-2003.
(265) A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrillation and additional risk factors. Permanent Atrial fibriLLAtion outcome Study using Dronedarone on top of standard therapy (PALLAS) [protocol]. Version 1 (February 26, 2010). [Cited 2012 Sept 25]. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa1109867.
(267) FSGS – Clinical trial [protocol]. Version 3c (June 20, 2005). [Cited 2012 Sept 25]. Available from: https://clinicalresearch.ccf.org/fsgs/docs/index_docs.html
(268) Lane SJ, Heddle NM, Arnold E, Walker I. A review of randomized controlled trials comparing the effectiveness of hand held computers with paper methods for data collection. BMC Med Inform Decis Mak 2006;6:23.
(272) Bedard M, Molloy DW, Standish T, Guyatt GH, D’Souza J, Mondadori C et al. Clinical trials in cognitively impaired older adults: home versus clinic assessments. J Am Geriatr Soc 1995;43:1127-1130.
(274) Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 2009;101:1624-1632.
(275) Cohen SB, Strand V, Aguilar D, Ofman JJ. Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy. Rheumatology (Oxford) 2004;43:704-711.
(276) Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 2004;22:3485-3490.
(277) Walther B, Hossin S, Townend J, Abernethy N, Parker D, Jeffries D. Comparison of electronic data capture (EDC) with the standard data capture method for clinical trial data. PLoS One 2011;6:e25348.
(280) Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. Br J Psychiatry 2000;176:249-252.
(286) Prevention Study Group. HEALTHY primary prevention trial protocol [protocol]. Version 1.4 (July 14, 2008). [Cited 2012 Sept 25]. Available from: http://www.healthystudy.org/
(287) HIV Prevention Trials Network and the International Maternal Pediatric and Adolescent AIDS Clinical Trials Network. HPTN 046: A phase III trial to determine the efficacy and safety of an extended regimen of nevirapine in infants born to HIV-infected women to prevent vertical HIV transmission during breastfeeding [protocol]. Version 3.0 (September 26, 2007). [Cited 2012 Sept 25]. Available from: http://www.hptn.org/research_studies/hptn046.asp
(288) Ioannidis JP, Bassett R, Hughes MD, Volberding PA, Sacks HS, Lau J. Predictors and impact of patients lost to follow-up in a long-term randomized trial of immediate versus deferred antiretroviral treatment. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:22-30.
(289) Ford ME, Havstad S, Vernon SW, Davis SD, Kroll D, Lamerato L et al. Enhancing adherence among older African American men enrolled in a longitudinal cancer screening trial. Gerontologist 2006;46:545-550.
(290) Couper MP, Peytchev A, Strecher VJ, Rothert K, Anderson J. Following up nonrespondents to an online weight management intervention: Randomized trial comparing mail versus telephone. J Med Internet Res 2007;9:e16.
(291) Renfroe EG, Heywood G, Foreman L, Schron E, Powell J, Baessler C et al. The end-of-study patient survey: methods influencing response rate in the AVID Trial. Control Clin Trials 2002;23:521-533.
(296) Kawado M, Hinotsu S, Matsuyama Y, Yamaguchi T, Hashimoto S, Ohashi Y. A comparison of error detection rates between the reading aloud method and the double data entry method. Control Clin Trials 2003;24:560-569.
(299) Gibson D, Harvey AJ, Everett V, Parmar MK. Is double data entry necessary? The CHART trials. CHART Steering Committee. Continuous, Hyperfractionated, Accelerated Radiotherapy. Control Clin Trials 1994;15:482-488.
(300) Ioannidis JPA, Evans SJW, Gøtzsche PC, O’Neill RT, Altman DG, Schulz KF et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141:781-788.
(303) Flow Investigators. Fluid lavage of open wounds (FLOW): design and rationale for a large, multicenter collaborative 2 x 3 factorial trial of irrigating pressures and solutions in patients with open fractures [protocol]. BMC Musculoskelet Disord 2010;11:85.
(304) Resuscitation Outcomes Consortium Prehospital Resuscitation using an IMpedance valve and Early vs Delayed analysis (ROC PRIMED) Trial. A factorial design of an active impedence threshold valve versus sham valve and analyze later versus analyze early [protocol]. Dec 2006 version. [Cited 2012 Sept 25]. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa1010821
(310) Yu L-M, Chan A-W, Hopewell S, Deeks JJ, Altman DG. Reporting on covariate adjustment in randomised controlled trials before and after revision of the 2001 CONSORT statement: a literature review. Trials 2010;11:59.
(313) Mohr JP, Moskowitz A, Ascheim D, Gelijns A, Parides M, et al. A Randomized multicenter clinical trial of Unruptured Brain AVMs (ARUBA): clinical protocol [protocol]. Version 3.0 (October 16, 2008). [Cited 2012 Sept 25]. Available from: http://research.ncl.ac.uk/nctu/ARUBA.html
(317) Akl EA, Briel M, You JJ, Sun X, Johnston BC, Busse JW et al. Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ 2012;344:e2809.
(325) Azuara-Blanco A, Burr JM, Cochran C, Ramsay C, Vale L, Foster P, et al. The effectiveness of early lens extraction with intraocular lens implantation for the treatment of primary angle-closure glaucoma (EAGLE): study protocol for a randomized controlled trial [protocol]. Trials 2011;12:133.
(326) Sydes MR, Altman DG, Babiker AB, Parmar MK, Spiegelhalter DJ, DAMOCLES Group. Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study. Clin Trials 2004;1:48-59.
(327) Floriani I, Rotmensz N, Albertazzi E, Torri V, De Rosa M, Tomino C et al. Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: a survey from the Italian National Monitoring Centre for Clinical Trials. Trials 2008;9:46.
(332) Bakker OJ, van Santvoort HC, van Brunschot S, Ali UA, Besselink MG, et al. Pancreatitis, very early compared with normal start of enteral feeding (PYTHON trial): design and rationale of a randomised controlled multicenter trial [protocol]. Trials 2011;12:73.
(342) Crowe BJ, Xia HA, Berlin JA, Watson DJ, Shi H, Lin SL et al. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clin Trials 2009;6:430-440.
(344) Ruiz-Canela M, Martinez-González MA, Gómez-Gracia E, Fernández-Crehuet J. Informed consent and approval by institutional review boards in published reports on clinical trials. N Engl J Med 1999;340:1114-1115.
(345) Breast Cancer International Research Group. BCIRG 006: Multicenter phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC–>T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (Herceptin®) (AC–>TH) and with docetaxel, carboplatin and trastuzumab (TCH) in the adjuvant treatment of node positive and high risk node negative patients with operable breast cancer containing the HER2 alteration [protocol]. Version 5 (June 27, 2008). [Cited 2012 Sept 25]. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa0910383
(347) Decullier E. Lhéritier V, Chapuis F. The activity of French research ethics committees and characteristics of biomedical research protocols involving humans: a retrospective cohort study. BMC Med Ethics 2005;6:e9.
(350) European Commission. Communication from the Commission — Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial (CT-1) (2010/C 82/01). Official Journal of the European Union 2010;53.
(351) Bond J, Wilson J, Eccles M, Vanoli A, Steen N, Clarke R, et al. Protocol for north of England and Scotland study of tonsillectomy and adeno-tonsillectomy in children (NESSTAC). A pragmatic randomised controlled trial comparing surgical intervention with conventional medical treatment in children with recurrent sore throats [protocol]. BMC Ear, Nose and Throat Disorders 2006;6:13.
(353) Ryan RE, Prictor MJ, McLaughlin KJ, Hill SJ. Audio-visual presentation of information for informed consent for participation in clinical trials. Cochrane Database of Systematic Reviews 2008, Issue 1. Art.No.: CD003717. DOI: 10.1002/14651858.CD003717.pub2.
(359) HIV Prevention Trials Network. HPTN 037: A phase III randomized study to evaluate the efficacy of a network-oriented peer educator intervention for the prevention of HIV transmission among injection drug users and their network members [protocol]. Version 2.0 (October 23, 2003). [Cited 2012 Sept 25]. Available from: http://www.hptn.org/research_studies/hptn037.asp
(360) World Association of Medical Editors Editorial Policy and Publication Ethics Committees. Conflict of interest in peer-reviewed medical journals. 2009. [Cited 2012 Sept 25]. Available from: http://www.wame.org/conflict-of-interest-in-peer-reviewed-medical-journals
(363) World Medical Association. WMA statement on conflict of interest. 2012. [Cited 2012 Sept 25]. Available from: http://www.wma.net/en/30publications/10policies/i3/
(365) Microbicide Trials Network. MTN-003: Phase 2B safety and effectiveness study of tenofovir 1% gel, tenofovir disproxil fumarate tablet and emtricitabine/tenofovir disoproxil fumarate tablet for the prevention of HIV infection in women [protocol]. Version 2.0 (December 31, 2010). [Cited 2012 Sept 25]. Available from: http://www.mtnstopshiv.org/news/studies/mtn003
(369) Participants in the 2006 Georgetown University Workshop on the Ancillary-Care Obligations of Medical Researchers Working in Developing Countries. The ancillary-care obligations of medical researchers working in developing countries. PLoS Med 2008;5:e90.
(370) Beta-Blocker Evaluation of Survival Trial (BEST) Protocol [protocol]. Version 1 (June 22, 1999). [Cited 2012 Sept 25]. Available from: https://biolincc.nhlbi.nih.gov/studies/best/.
(373) Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-1345.
(374) Cowley AJ, Skene A, Stainer K, Hampton JR. The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias. Int J Cardiol 1993;40:161-166.
(378) Emerson GB, Warme WJ, Wolf FM, Heckman JD, Brand RA, Leopold SS. Testing for the presence of positive-outcome bias in peer review: a randomized controlled trial. Arch Intern Med 2010;170:1934-1939.
(386) Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008;299:1800-1812.
(389) International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication. 2010. [Cited 2012 Sept 25]. Available from: http://www.icmje.org/urm_full.pdf
(391) Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM et al. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ 2009;339:b4330.
(393) Wolinsky FD, Vander Weg MW, Howren MB, Jones MP, Martin R, Luger TM, et al. Protocol for a randomized controlled trial to improve cognitive functioning in older adults: the Iowa Healthy and Active Minds Study [protocol]. BMJ Open 2011;1:e000218.
(396) Wieseler B, Kerekes MF, Vervoelgyi V, McGauran N, Kaiser T. Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. BMJ 2012;344:d8141.
(398) European Medicines Agency. European Medicines Agency policy on access to documents (related to medicinal products for human and veterinary use) (EMA/110196/2006). 2010. [Cited 2012 Sept 25]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/11/WC500099473.pdf
(401) Committee on Responsibilities of Authorship in the Biological Sciences, National Research Council. Sharing publication-related data and materials: Responsibilities of authorship in the life sciences. Washington, D.C.: National Academies Press; 2003.
(406) The Royal Science Policy Centre. Science as an open enterprise. June 2012. [Cited 2012 Sept 25]. Available from: http://royalsociety.org/uploadedFiles/Royal_Society_Content/policy/projects/sape/2012-06-20-SAOE.pdf
(409) Sharing of Materials, Methods, and Data. 2011. [Cited 2012 Sept 25]. Available from: http://www.plosone.org/static/policies.action
(410) Trials. Instructions for authors. Editorial policies. 2012. [Cited 2012 Sept 25]. Available from: http://www.trialsjournal.com/authors/instructions
(411) National Institutes of Health. Final NIH statement on sharing research data. Feb 26, 2003. 2003. [Cited 2012 Sept 25]. Available from: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html
(413) BMJ Publishing Group Ltd. Instructions for authors. 2012. [Cited 2012 Sept 25]. Available from: http://bmjopen.bmj.com/site/about/guidelines.xhtml
(415) Paris A, Cracowski JL, Ravanel N, Cornu C, Gueyffier F, Deygas B et al. [Readability of informed consent forms for subjects participating in biomedical research: updating is required]. Presse Med 2005;34:13-18.
(416) Southwest Oncology Group. Chemoprevention of prostate cancer with finasteride (Proscar®) Phase III [protocol]. Aug 2001 version. [Cited 2012 Sept 25]. Available from: http://swog.org/visitors/pcpt/